Live Markets »News & Advice»Company News»Company News Details
Company News Details

Cipla launches generic hepatitis C drug

BS Reporter/Mumbai 22 Dec 15 | 12:47 AM
Related to : Cipla Ltd
 Cipla Ltd

BSE   22 Jun 18 | 12:00 AM

614.00  12.35 (2.05%)

NSE   22 Jun 18 | 12:00 AM

615.75  12.25 (2.03%)

Drug maker Cipla on Monday announced the launch of a generic version of anti-hepatitis drug Ledipasvir-Sofosbuvir in the domestic market.

The drug is used for treating the hepatitis C virus. About 12-18 million Indians are suffering from it while globally the number is about 185 million.

Related Stories

    No Related Stories Found
Widgets Magazine

Last year, pharma company Gilead Sciences signed non-exclusive licencing agreements with seven companies, including Cipla, for the manufacture and distribution of the drug in India.

Cipla also announced the launch of a patient support programme to create awareness amongst people and to cater to existing patients.

Managing Director and Global Chief Executive Officer Subhanu Saxena said, “The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus."

Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients, Cipla said.

The company’s current portfolio includes over 1,500 products across therapeutic categories.

Cipla was trading at Rs 646.15, up 0.62 per cent, on the BSE.

(With inputs from agencies)

Widgets Magazine


Company Price Gain (%)
Sun Pharma.Inds.576.303.91
M & M908.152.78
H D F C1,902.402.54
Axis Bank524.652.22
Bharti Airtel374.601.74


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine